---
title: "Restless Legs Syndrome"
description: "Clinical decision support for restless legs syndrome (rls) / willis-ekbom disease diagnosis and management"
version: "1.0"
setting: "HOSP, OPD, ICU"
---

# Restless Legs Syndrome

**VERSION:** 1.0
**CREATED:** January 29, 2026
**REVISED:** January 29, 2026
**STATUS:** Complete

---

**DIAGNOSIS:** Restless Legs Syndrome (RLS) / Willis-Ekbom Disease

**ICD-10:** G25.81 (Restless legs syndrome), G25.89 (Other specified extrapyramidal and movement disorders), G47.61 (Periodic limb movement disorder)

**SYNONYMS:** Restless legs syndrome, RLS, Willis-Ekbom disease, WED, restless leg syndrome, Ekbom syndrome, anxietas tibiarum, leg jitters, nocturnal leg cramps (often confused with), periodic limb movement disorder, PLMD, akathisia (related)

**SCOPE:** Diagnosis and management of restless legs syndrome in adults. Covers diagnostic criteria, workup for secondary causes, pharmacologic and non-pharmacologic treatment, and prevention of augmentation. Excludes periodic limb movement disorder as separate entity, akathisia, and leg cramps.

---

**DEFINITIONS:**
- **Restless Legs Syndrome (RLS):** Neurological sensorimotor disorder characterized by urge to move legs, usually accompanied by uncomfortable sensations, with circadian pattern and relief with movement
- **Augmentation:** Paradoxical worsening of RLS with dopaminergic treatment: earlier onset, spread to arms, shorter latency, increased intensity
- **Periodic Limb Movements of Sleep (PLMS):** Repetitive limb movements during sleep, often associated with RLS (but can occur independently)
- **Refractory RLS:** RLS not adequately controlled by standard treatments

---

**DIAGNOSTIC CRITERIA (IRLSSG 2014):**

**All 5 essential criteria must be met:**

1. **Urge to move the legs** usually accompanied by uncomfortable sensations in the legs (may occur without)
2. **Symptoms worsen during rest or inactivity** (lying, sitting)
3. **Symptoms partially or totally relieved by movement** (walking, stretching) at least as long as activity continues
4. **Symptoms occur exclusively or predominantly in evening/night** (worse at night than day)
5. **Not solely accounted for by another condition** (leg cramps, positional discomfort, myalgia, venous stasis, leg edema, arthritis, habitual foot tapping, akathisia)

**Supportive Features:**
- Family history of RLS
- Response to dopaminergic therapy
- Periodic limb movements (on PSG or actigraphy)

**Severity (IRLS Rating Scale):**
- Mild: 0-10
- Moderate: 11-20
- Severe: 21-30
- Very severe: 31-40

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

---

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs (All Patients)

| Test | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------|:--:|:----:|:---:|:---:|-----------|----------------|
| Serum ferritin (CPT 82728) | - | ROUTINE | ROUTINE | - | Iron deficiency is treatable cause; target >75 ng/mL | >75 ng/mL (>100 preferred) |
| Serum iron (CPT 83540) | - | ROUTINE | ROUTINE | - | Iron deficiency assessment | Normal |
| TIBC (CPT 83550) | - | ROUTINE | ROUTINE | - | Iron deficiency assessment | Normal |
| Transferrin saturation (CPT 84466) | - | ROUTINE | ROUTINE | - | Target >20% | >20% |
| CBC (CPT 85025) | - | ROUTINE | ROUTINE | - | Anemia workup | Normal |
| CMP (CPT 80053) | - | ROUTINE | ROUTINE | - | Renal function (uremia can cause RLS), electrolytes | Normal |
| TSH (CPT 84443) | - | ROUTINE | ROUTINE | - | Thyroid dysfunction | Normal |
| Glucose (CPT 82947) / HbA1c (CPT 83036) | - | ROUTINE | ROUTINE | - | Diabetes can cause neuropathy mimicking RLS | Normal |

### 1B. Extended Workup (Second-line)

| Test | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------|:--:|:----:|:---:|:---:|-----------|----------------|
| Vitamin B12 (CPT 82607) | - | ROUTINE | ROUTINE | - | Deficiency can cause neuropathy | >400 pg/mL |
| Folate (CPT 82746) | - | ROUTINE | ROUTINE | - | Deficiency | Normal |
| Magnesium (CPT 83735) | - | ROUTINE | ROUTINE | - | Deficiency can contribute | Normal |
| BUN/Creatinine | - | ROUTINE | ROUTINE | - | Uremic RLS | Normal |
| Pregnancy test | - | ROUTINE | ROUTINE | - | RLS common in pregnancy; affects treatment | Document |

### 1C. Rare/Specialized

| Test | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------|:--:|:----:|:---:|:---:|-----------|----------------|
| Nerve conduction studies (CPT 95907-95913) / EMG (CPT 95885) | - | - | EXT | - | If neuropathy suspected | Rule out neuropathy mimics |
| ANA (CPT 86235), anti-SSA/SSB | - | - | EXT | - | If autoimmune neuropathy suspected | Negative |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| Clinical diagnosis | - | ROUTINE | ROUTINE | - | At evaluation | All 5 diagnostic criteria met | None |

### 2B. Extended

| Study | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| Polysomnography (PSG) (CPT 95810) | - | - | EXT | - | If PLMD suspected or other sleep disorder | PLMS >15/hour supports diagnosis | Not required for diagnosis |
| Actigraphy | - | - | EXT | - | Objective movement assessment | Document periodic movements | None |
| MRI spine (CPT 72141) | - | - | EXT | - | If radiculopathy suspected | Rule out structural cause | Per MRI |
| Doppler ultrasound (legs) | - | - | EXT | - | If venous insufficiency suspected | Rule out venous disease | None |

---

## 3. TREATMENT

### 3A. Non-Pharmacologic Treatment (All Patients)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
| --- | --- | --- | --- | --- | --- | :--: | :--: | :--: | :--: |
| Sleep hygiene | - | - | Regular sleep schedule, cool room, limit screen time | None | Foundation of treatment | - | ROUTINE | ROUTINE | - |
| Avoid triggers | - | - | Avoid alcohol, caffeine, nicotine (especially evening) | None | Critical | - | ROUTINE | ROUTINE | - |
| Moderate exercise | - | - | Regular exercise, but avoid intense exercise close to bedtime | None | Helps symptoms | - | - | ROUTINE | - |
| Leg massage/stretching | - | - | Gentle stretching, massage before bed | None | May provide relief | - | ROUTINE | ROUTINE | - |
| Hot bath | - | - | Warm bath before bedtime | None | Relaxation | - | - | ROUTINE | - |
| Mental alerting activities | - | - | Crosswords, video games can distract during symptoms | None | Useful for mild cases | - | - | ROUTINE | - |
| Pneumatic compression devices | - | - | Sequential compression 1 hour before bed | DVT, arterial disease | Limited evidence | - | - | EXT | - |

### 3B. Iron Replacement (If Ferritin <75 ng/mL)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
| --- | --- | --- | --- | --- | --- | :--: | :--: | :--: | :--: |
| Ferrous sulfate | - | - | 325 mg :: - :: daily :: 325 mg (65 mg elemental iron) with vitamin C 100 mg, on empty stomach, daily or every other day | Iron overload, hemochromatosis | Ferritin q3 months; GI side effects | - | ROUTINE | ROUTINE | - |
| Ferrous gluconate | PO | - | 324 mg :: PO :: daily :: 324 mg (36 mg elemental iron) daily; better tolerated | Same | Same | - | ROUTINE | ROUTINE | - |
| IV iron (ferric carboxymaltose) (CPT 96365) | IV | - | 1000 mg :: IV :: once :: 1000 mg IV once (if oral intolerant or severe deficiency); may repeat | Iron overload, infection | Ferritin in 8 weeks; faster response | - | ROUTINE | ROUTINE | - |
| IV iron sucrose (CPT 96365) | IV | - | 200 mg :: IV :: - :: 200 mg IV Ã— 5 doses over 2 weeks | Same | Same | - | ROUTINE | ROUTINE | - |

### 3C. First-Line Pharmacologic Treatment - Alpha-2-Delta Ligands (PREFERRED)

**Note:** Alpha-2-delta ligands (gabapentinoids) are now FIRST-LINE due to lower augmentation risk than dopamine agonists.

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
| --- | --- | --- | --- | --- | --- | :--: | :--: | :--: | :--: |
| Gabapentin | PO | - | 300 mg :: PO :: QHS :: Start 300 mg QHS; titrate by 300 mg every few days to 900-1800 mg QHS | Renal impairment (adjust) | Sedation, dizziness, edema | - | ROUTINE | ROUTINE | - |
| Gabapentin enacarbil (Horizant) | PO | - | 600 mg :: PO :: daily :: 600 mg daily at ~5 PM; FDA approved for RLS | Renal impairment (adjust) | Sedation, dizziness | - | - | ROUTINE | - |
| Pregabalin | PO | - | 75 mg :: PO :: QHS :: Start 75 mg QHS; titrate to 150-300 mg QHS | Renal impairment (adjust) | Sedation, dizziness, weight gain | - | ROUTINE | ROUTINE | - |

### 3D. Second-Line Pharmacologic Treatment - Dopamine Agonists

**AUGMENTATION WARNING:** Dopamine agonists have significant augmentation risk (up to 70% over 10 years). Use lowest effective dose. Monitor closely.

| Treatment | Route | Indication | Dosing | Pre-Treatment Requirements | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
| --- | --- | --- | --- | --- | --- | --- | :--: | :--: | :--: | :--: |
| Pramipexole (Mirapex) | PO | - | 0.125 mg :: PO :: - :: Start 0.125 mg 2-3h before bedtime; titrate by 0.125 mg q4-7 days; max 0.5 mg (keep dose LOW) | - | Severe renal impairment | AUGMENTATION, ICDs, sleepiness | - | ROUTINE | ROUTINE | - |
| Ropinirole (Requip) | PO | - | 0.25 mg :: PO :: - :: Start 0.25 mg 1-3h before bedtime; titrate by 0.25 mg q4-7 days; max 4 mg (keep dose LOW) | - | Severe hepatic impairment | AUGMENTATION, ICDs, sleepiness | - | ROUTINE | ROUTINE | - |
| Rotigotine patch (Neupro) | Transdermal | - | 1 mg :: PO :: - :: Start 1 mg/24h patch; titrate by 1 mg/week; max 3 mg/24h | - | Sulfite allergy | AUGMENTATION, ICDs, skin reactions | - | ROUTINE | ROUTINE | - |

### 3E. Third-Line / Refractory Treatment

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
| --- | --- | --- | --- | --- | --- | :--: | :--: | :--: | :--: |
| Low-dose opioids | PO | - | 5-15 mg :: PO :: QHS :: Oxycodone 5-15 mg QHS or tramadol 50-100 mg QHS; RESERVE for refractory cases | Addiction risk, respiratory depression, apnea | Dependence, respiratory | - | - | EXT | - |
| Extended-release oxycodone | PO | - | 10-20 mg :: PO :: QHS :: 10-20 mg QHS; for severe refractory RLS | Same | Same | - | - | EXT | - |
| Methadone (specialist use) | PO | - | 5-10 mg :: PO :: QHS :: 5-10 mg QHS; specialist prescribing only | Same; QT prolongation | QTc, respiratory | - | - | EXT | - |
| Buprenorphine (specialist use) | - | - | 0.2-0.8 mg :: - :: QHS :: 0.2-0.8 mg SL QHS; may have lower abuse potential | Same | Same | - | - | EXT | - |

### 3F. Managing Augmentation

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
| --- | --- | --- | --- | --- | --- | :--: | :--: | :--: | :--: |
| Recognize augmentation | - | - | - | - | Key to management | - | ROUTINE | ROUTINE | - |
| Discontinue dopamine agonist | - | - | - | - | "Washout" period difficult | - | ROUTINE | ROUTINE | - |
| Bridge with opioid | - | - | - | - | Temporary use | - | ROUTINE | ROUTINE | - |
| Switch to alpha-2-delta ligand | - | - | - | - | New first-line | - | ROUTINE | ROUTINE | - |
| IV iron | IV | - | - | - | Helpful during transition | - | ROUTINE | ROUTINE | - |

---

## 4. OTHER RECOMMENDATIONS

### 4A. Referrals & Consults

| Recommendation | ED | HOSP | OPD | ICU | Indication |
|----------------|:--:|:----:|:---:|:---:|------------|
| Sleep medicine specialist | - | - | ROUTINE | - | Refractory RLS, PLMD evaluation, PSG needed |
| Neurology | - | ROUTINE | ROUTINE | - | Diagnostic uncertainty, refractory cases |
| Hematology | - | - | ROUTINE | - | Significant iron deficiency, iron infusion |
| Nephrology | - | ROUTINE | ROUTINE | - | Uremic RLS (ESRD patients) |
| Psychiatry | - | - | ROUTINE | - | Impulse control disorders on dopamine agonists |
| Pain management | - | - | EXT | - | Opioid management in refractory cases |

### 4B. Patient/Family Instructions

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| RLS is a real neurological condition, not psychological | - | ROUTINE | ROUTINE |
| Iron levels should be optimized (ferritin >75) | - | ROUTINE | ROUTINE |
| Avoid caffeine, alcohol, and nicotine, especially in evening | - | ROUTINE | ROUTINE |
| Maintain regular sleep schedule | - | ROUTINE | ROUTINE |
| Report symptoms of augmentation: earlier onset, spreading to arms | - | ROUTINE | ROUTINE |
| Report impulse control changes if on dopamine agonists (gambling, shopping) | - | ROUTINE | ROUTINE |
| Exercise regularly but not close to bedtime | - | ROUTINE | ROUTINE |
| Many medications can worsen RLS - check with doctor before starting new meds | - | ROUTINE | ROUTINE |
| RLS Foundation (rls.org) for resources and support | - | - | ROUTINE |

### 4C. Medications That May Worsen RLS (Avoid/Minimize)

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Antihistamines (diphenhydramine, hydroxyzine) | ROUTINE | ROUTINE | ROUTINE |
| Antidopaminergic antiemetics (metoclopramide, prochlorperazine) | ROUTINE | ROUTINE | ROUTINE |
| Antipsychotics (especially typical; atypical less so) | ROUTINE | ROUTINE | ROUTINE |
| SSRIs/SNRIs (may worsen in some patients) | - | ROUTINE | ROUTINE |
| TCAs (may worsen in some patients) | - | ROUTINE | ROUTINE |
| Lithium | - | ROUTINE | ROUTINE |

---

## 5. DIFFERENTIAL DIAGNOSIS

| Alternative Diagnosis | Key Distinguishing Features | Tests to Differentiate |
|-----------------------|----------------------------|------------------------|
| Nocturnal leg cramps | Painful muscle contraction, sudden onset, relieved by stretching | Clinical; no urge to move |
| Peripheral neuropathy | Numbness/tingling, burning, not worse at rest, not circadian | EMG/NCS; different symptom pattern |
| Akathisia | Inner restlessness, not limb-specific, medication-induced (antipsychotics) | Medication history; involves whole body |
| Positional discomfort | Relieved by position change; not circadian | Clinical |
| Varicose veins/venous stasis | Visible veins, edema, worse with standing | Doppler ultrasound |
| Arthritis | Joint pain, stiffness, not circadian | Clinical; imaging |
| Peripheral artery disease | Claudication, worse with activity, cool extremities | ABI, vascular studies |
| Radiculopathy | Dermatomal distribution, back pain | MRI spine; EMG |
| Growing pains (children) | Bilateral, no urge to move, different demographics | Clinical |
| Habitual foot tapping/leg bouncing | Voluntary, not uncomfortable, no urge | Clinical |
| Periodic limb movement disorder | Movements during sleep; no awake symptoms | PSG; RLS is awake symptom |

## 6. MONITORING PARAMETERS

| Parameter | ED | HOSP | OPD | ICU | Frequency | Target/Threshold | Action if Abnormal |
|-----------|:--:|:----:|:---:|:---:|-----------|------------------|-------------------|
| IRLS severity scale | - | ROUTINE | ROUTINE | - | Each visit | Improving score | Adjust treatment |
| Ferritin | - | ROUTINE | ROUTINE | - | q3-6 months until stable | >75-100 ng/mL | Iron supplementation |
| Transferrin saturation | - | ROUTINE | ROUTINE | - | With ferritin | >20% | Iron supplementation |
| Augmentation screening | - | ROUTINE | ROUTINE | - | Each visit (if on DA) | Absent | Stop/switch dopamine agonist |
| Impulse control screening | - | ROUTINE | ROUTINE | - | Each visit (if on DA) | Absent | Stop dopamine agonist |
| Sleep quality | - | ROUTINE | ROUTINE | - | Each visit | Improved | Adjust treatment |
| Renal function (if uremic) | - | ROUTINE | ROUTINE | - | Per nephrology | Stable | Dialysis optimization |

## 7. DISPOSITION CRITERIA

| Disposition | Criteria |
|-------------|----------|
| Outpatient management | Most patients; mild-moderate RLS |
| Sleep medicine referral | Refractory RLS, PLMD suspected, PSG needed |
| Hematology referral | Significant iron deficiency, IV iron needed |
| Neurology referral | Diagnostic uncertainty, refractory cases, augmentation management |
| Follow-up frequency | q1-3 months initially; less frequent once stable |

## 8. EVIDENCE & REFERENCES

| Recommendation | Evidence Level | Source |
|----------------|----------------|--------|
| IRLSSG diagnostic criteria | Class I | [Allen et al., Sleep Med 2014](https://pubmed.ncbi.nlm.nih.gov/25023924/) |
| Iron supplementation if ferritin <75 | Class I, Level A | Multiple RCTs; AASM Guidelines |
| Alpha-2-delta ligands first-line | Class I, Level A | Updated guidelines 2016; lower augmentation risk |
| Gabapentin enacarbil FDA approved | Class I, Level A | FDA approval; multiple RCTs |
| Pregabalin effective | Class I, Level A | Multiple RCTs |
| Dopamine agonists effective but augmentation risk | Class I, Level A | Multiple RCTs; 70% augmentation at 10 years |
| Low-dose opioids for refractory RLS | Class II, Level B | Limited RCTs |
| Avoid antihistamines, antidopaminergics | Class II, Level B | Observational data |

---

## NOTES

- RLS is primarily a clinical diagnosis based on 5 essential criteria
- Iron deficiency is the most important reversible cause - check ferritin in ALL patients
- Target ferritin >75 ng/mL (many experts prefer >100)
- Alpha-2-delta ligands (gabapentin, pregabalin) are now FIRST-LINE due to lower augmentation risk
- Dopamine agonists cause augmentation in up to 70% of patients over 10 years
- If using dopamine agonists, use LOWEST effective dose
- Augmentation = earlier onset, spread to arms, shorter latency, higher intensity
- Many common medications worsen RLS (antihistamines, metoclopramide, antipsychotics)
- RLS is common in pregnancy (~25%); iron deficiency is often the cause
- RLS is common in ESRD (~30%); optimizing dialysis and treating iron deficiency helps
- Opioids are reserved for refractory cases; effective but addiction concern

---

## CHANGE LOG

**v1.0 (January 29, 2026)**
- Initial template creation
- IRLSSG 2014 diagnostic criteria
- Alpha-2-delta ligands positioned as first-line (per updated guidelines)
- Augmentation management section
- Medications to avoid listed
- Iron supplementation emphasized
